sufficient to distinguish between the luminal A and B sub-groups in HR-positive, HER2-negative breast cancer and does not account for different clinical progresses of luminal type breast cancer patients who are in the same stage and receive similar treatments. In order to explain this difference and better differentiate between patients who may not require chemotherapy as part of adjuvant therapy and those who need to have addition of CT to their hormone therapy, various gene expression analyses have been and are being studied retrospectively and prospectively.
Gene Expression Profiling
Amsterdam 70-gene Profile-MammaPrint dx Test (Table 3) The first one of these tests is MammaPrint dx 70-gene expression analysis, which was developed by the Netherlands Cancer Institute. They identified 70 genes which differentiate between patients diagnosed with breast cancer as good profile and poor profile depending on the risk of developing metastasis within 5 years as of diagnosis. This gene profile was developed based on a gene study conducted with 78 ALN-negative patients below the age of 55 and diagnosed with invasive breast cancer a tumor size <5 cm (13, 14) . The test is conducted using the micro-array-based gene expression profiling technique. Fresh tissue sample or frozen archival material and formalin-fixed paraffinembedded (FFPE) material are used for the test (9, 15) . Several studies have demonstrated that MammaPrint is an independent prognostic factor in patients with ALN-negative breast cancer (16) (17) (18) . It has been seen that 35% of patients that seemed to have high risk disease actually had low risk and 14% of patients that seemed to be in the low risk group actually had high risk in this program as compared to the adjuvant online program (19) .
The MammaPrint test is recommended for early breast cancer of all ages with tumor size <5 cm, with the ALN 0-3 positive cases, and estrogen receptor (ER)-positive or negative tumors (8) . It was approved by Food and Drug Administration (FDA) in 2007 for marketing as a prognostic test, but not to select therapy or predict response to therapy (15) . Results are reported as low risk (13% chance of developing distant metastases at 10 years without adjuvant treatment) or high risk (56% chance of developing distant metastases at 10 years without adjuvant treatment).
For the prospective validation of the test, an international, randomized, Phase-3 MINDACT study (Microarray in Node-Negative and 1 to 3 Positive Lymph Node Disease May Avoid Chemotherapy-EORTC 10041/BIG 3-04 study) has been scheduled (20) . In this study, 6693 patients with early-stage breast cancer (HR+, Nod 1-3 positive or negative, HER2-) were recruited. The genomic risks (using the 70-gene signature) and clinical-pathological risks (using a modified version of Adjuvant Online) of the patients were identified and the aim has been set as comparing their effectiveness in the adjuvant therapy selection. CT was not provided for the group with low genomic and clinical risk. CT was provided for the group with high genomic and clinical-pathological risk. In patients with discordant risk results, either the genomic risk or the clinical-pathological risk was used to determine the use of chemotherapy and hormone therapy or only hormone therapy. The primary aim of the study was to determine whether patients with high clinical risk and low genomic risk had requirement for CT. According to the assessment of 1550 patients with high clinical risk and low genomic risk, metastasis-free survival rate was found to be 94.7% in patients not receiving CT, which was 1.5% lower than the patients that were on CT. The rates of distant metastasis-free survival were found to be similar among patients that were node-negative or positive, ER-positive and HER2-. Based on these results, the researchers concluded that 46% of the patients with low genomic risk and high clinical risk did not require CT.
MammaPrint is featured as a prognostic parameter in the St Gallen and ESMO (European Society of Medical Oncology) guidelines (3, 21) .
In the 8th Breast Cancer Staging System of American Joint Committee on Cancer (AJCC), which is to be published in 2018, gene expression profiling is included in breast cancer staging as a prognostic panel (22) . 169
Güler. Gene Expression Profiling in Early Breast Cancer One of these panels is MammaPrint (when available as stage modifiers): For patients with HR-positive, HER2 negative , and ALN negative tumors, a MammaPrint low-risk score, regardless of T size, places the tumor in the same prognostic category as T1a-T1b N0M0 (Level of Evidence II).
21-Gene Recurrence Score assay (Oncotype DX) (Table 3)
The Oncotype DX Breast Cancer Assay is a commercially available reverse transcriptase-polymerase chain reaction (RT-PCR) based signature. It evaluates the mRNA levels of 21 genes (16 cancer-related genes and 5 reference genes) (8, 9, 15) . The expression of these 21 genes is reported as a single Recurrence Score (RS), which ranges between 0 and 100. The test is routinely performed on FFPE tissue specimens.
Patients are divided into 3 risk groups depending on the risk for distant metastasis in ten years: preted as being a 'predictor of distant relapse in ER+ node negative disease.' These results were also tested in the NSABP B-20 study (HR positive disease with negative axillary nodes; adjuvant tamoxifen versus CMF + tamoxifen) and the contribution of CT as per the risk groups was investigated (24): It was seen that the addition of CT to tamoxifen for patients in the low risk group decreased the 10-year risk for distant metastasis by only 1.1% while the addition of CT to tamoxifen for patients in the high risk group reduced the 10-year risk for distant metastasis significantly by 27.6%. The benefit of the addition of CT to hormonal therapy in the intermediate risk group was not showed to be clinically significant.
The action to be taken for patients in the intermediate risk group could not be completely elucidated. Should it be only HT or CT and HT? In order to shed light onto this question, a prospective randomized study was initiated in the year 2006 (Trial Assigning Individualized Options for Treatment-TAILORx; prospective clinical validation study) (25) . In this study, 10.253 patients (HR-positive and HER2-negative with negative axillary nodes) from 6 countries and 900 study sites were included between the years 2006 and 2010. The patients were divided into groups as follows: RS<11 low risk group (only endocrine treatment), RS 11-25 intermediate risk group (divided into two arms: only HT and CT + HT) and RS>25 high risk group (CT and HT). As part of HT, tamoxifen or aromatase inhibitor (AI) or tamoxifen followed by AI were administered for 5 years and tamoxifen or AI along with ovarian suppression were used in 3% of the patients. During the ESMO 2015 meeting, the results of the low-risk group (15.9% of all patients;-1626 patients) were presented as follows: 5-year invasive disease free survival: 93.8%; recurrence-free survival: 98.7%; distant recurrence-free survival: 99.3% and overall survival: 98%. Recurrence events were uncommon regardless of the histologic grade, tumor size and were not significantly affected by younger age at diagnosis in this low risk group.
The results of the study also prospectively showed that only adjuvant HT was sufficient for patients with low risk according to the 21 gene expression analysis (Level IA evidence). It is expected that the results of the intermediate risk group will be announced within the year 2017.
The prognostic and predictive validity of Oncotype DX was also retrospectively evaluated in 4 randomized phase-3 studies [SWOG 8814, ATAC (Adjuvant Tamoxifen or Anastrozole), NSABP-B28 and ECOG 2197 studies] including ALN positive and HR-positive cases (26) (27) (28) (29) (30) . It was seen that CT was beneficial in distinguishing nodepositive patients who would benefit from CT (Predictor of likelihood of chemotherapy benefit in ER+ Node positive disease). Its prospective validation in the node-positive patients was demonstrated in the West German Study Group Plan B Randomized Phase-3 study, the Clalit Registry study conducted in Israel and the SEER real-life observational study (31) (32) (33) . In all these studies, the 5-year survival rate of patients in the low risk group is >95%.
Other ongoing trials (RxPONDER and OPTIMA) are evaluating whether adjuvant CT is beneficial in patients with HR-positive, HER2-negative breast cancer with 1 to 3 positive ALNs and a RS of 25 or less (7, 8) .
Oncotype DX is included as a prognostic and predictive tests in the ESMO, St Gallen, NCCN (National Comprehensive Cancer Network; includes 1 to 3 positive nodes) and ASCO (American Society of Clinical Oncology; node negative only) guidelines (3, 4, 21, 34 ).
The Oncotype DX staging system has been included in the 8th breast staging system by AJCC (when available as stage modifiers) (22) : For patients with HR-positive, HER2-negative and ALN-negative tumors, Oncotype DX recurrence score less than 11, regardless of T size, places the tumor in the same prognostic category as T1a-T1b N0M0, and the tumor is staged using the AJCC prognostic stage group table as stage I (Level of Evidence I).
Predictor analysis of microarray 50 risk of recurrence score (PAM50-ROR) (Table 3) The PAM50 is a test that uses 50 classifier genes and 5 control genes. The microarray technique is employed and study is done on FFPE tissues with quantitative RT-PCR technology (8, 9, 15) . Along with the tumor diameter and four main intrinsic sub-types are provided along with the risk of recurrence (ROR). The PAM50 score is reported on a 0-100 scale (ROR score of risk of recurrence), which is correlated with the probability of distant recurrence at ten years for women with HR positive, early-stage node-negative or node 1-3 positive breast cancer. Patients are divided into high (>20%), intermediate (10 to 20%) and low (<10%) risk groups. It was retrospectively tested in the ATAC and ABCSG-8(Austrian Breast Cancer Study Group 8) studies and demonstrated to be an important prognostic indicator for both ALNnegative and ALN-positive patients in all sub-groups (35, 36) . It is an FDA-approved test (9, 34) .
It has been included in the 8th breast cancer staging system by the AJCC (when available as stage modifiers) (22) : For patients with HRpositive, HER2-negative and ALN-negative tumors, a PAM50 ROR score in the low-range, regardless of T size, places the tumor in the same prognostic category as T1a-T1b N0M0 (Level of Evidence II).
Breast Cancer Index (BCI) (Table 3)
Breast Cancer Index is a combination of molecular grade index (MGI) and HOXB13-to-IL17BR expression ratio (H:I ratio). Studies conducted have shown that it is effective in anticipating treatment response and prognosis in ER-positive tumors (37, 38) . Three risk groups are identified: low, intermediate and high risk. Its clinical usability is still being investigated. ASCO states that it can be used in making a decision for adjuvant therapy in HR-positive, HER2-negative and node-negative disease while it is not recommended to be used in node-positive disease (34) .
EndoPredict (Table 3)
It involves RNA-based analysis of 11 genes (8 cancer related and 3 reference genes). Its prognostic value was validated using the data from ABCSG-6 and ABCSG-8 trials (39) . ASCO states that it can be used in making a decision for adjuvant therapy in HR-positive, HER2-negative and node-negative disease while it is not recommended to be used in node-positive disease (34) . It is a test which can also be used to make a decision for prolonged adjuvant therapy.
Breast Cancer Index and EndoPredict (when available as stage modifiers) tests are also included as part of the prognostic panel in the 8th staging booklet (Level of evidence II) (22) (Table 3 ).
Other assays include the Rotterdam 76-gene signature, genomic grade index, molecular grade index, etc. There are not sufficient data about the prognostic significance of these arrays (9, 15, 34, 40, 41) . Further studies are needed.
Conclusion
Gene expression analyses are beneficial in determining the prognosis and selecting therapy for luminal type breast cancers (HER2-negative, HR-positive). Even though these tests are costly, studies performed have shown that they are actually cost-efficient (42, 43) . They are included in reimbursement schemes in the USA and Europe whereas they are not included in the reimbursement program in Turkey and many other countries. Therefore, studies can be conducted only on a limited group of patients. Studies conducted in Turkey have demonstrated that Oncotype DX has significantly correlated with PR and Ki-67 score of the tumor, and has a significant contribution to determining the therapy selection (44, 45) . In another study from Turkey, Oncotype DX test was found as cost-effective in patients with early stage breast cancer (46) .
It should also be kept in mind that gene expression analyses may yield false results in rarely seen tumors such as breast cancers showing neuroendocrine differentiation and in mixed morphologies (47) . Furthermore, the stromal cells and inflammatory cells around the tumor tissue and the normal breast tissue are not included in the analysis. The ratio of non-neoplastic cells in the analysis may change the expression profile and the prognostic signature. In the second-generation gene expression analyses, myoepithelial and stromal cells are also assessed in addition to the epithelial cancer cells (8) .
There are no gene expression tests available yet to determine the therapy selection for other intrinsic types of breast cancers. Various gene expression analyses and second generation gene expression analysis studies are ongoing with the aims of determining the drug selection in endocrine treatment, selecting the agent to be used in chemotherapy and predicting treatment to neoadjuvant therapy (8) . Technological advancements and developments in the field of molecular biology and genetics will enable us to provide individualized therapies for our patients.
Peer-review: Externally peer-reviewed.
